Principal Investigator
Peter Hosein
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231325
Clinical Trial Summary
A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination with Nivolumab and Ipilimumab in Patients with Poorly Differentiated Neuroendocrine Carcinomas or Well-Differentiated High-Grade (Grade 3) Neuroendocrine Tumors
Phase
Phase I
Funding Agency/Sponsor
Institutional
Disease
Stomach and Esophageal Cancer
Contact Information
Phone Number
305-243-2647